| Original language | English |
|---|---|
| Pages (from-to) | 1971-1973 |
| Number of pages | 3 |
| Journal | Diabetologia |
| Volume | 52 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 2009 |
Keywords
- Cancer
- Insulin analogues
- Insulin glargine
- Insulin therapy
- Malignancy
- NPH insulin
- Type 2 diabetes
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes : Findings from a 5 year randomised, open-label study. / Rosenstock, J.; Fonseca, V.; McGill, J. B.; Riddle, M.; Hallé, J. P.; Hramiak, I.; Johnston, P.; Davis, M.
In: Diabetologia, Vol. 52, No. 9, 09.2009, p. 1971-1973.Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes
T2 - Findings from a 5 year randomised, open-label study
AU - Rosenstock, J.
AU - Fonseca, V.
AU - McGill, J. B.
AU - Riddle, M.
AU - Hallé, J. P.
AU - Hramiak, I.
AU - Johnston, P.
AU - Davis, M.
N1 - Funding Information: Duality of interest J. Rosenstock has received grants for research from and/or has been a consultant to Amylin, Boehringer-Ingelheim, Bristol-Myers Squibb, Centocor, Eli Lilly, Emisphere, GlaxoSmithKline, Johnson & Johnson, MannKind, Merck, Novartis, Novo Nordisk, Pfizer, Roche, Sankyo, sanofi-aventis and Takeda. V. Fonseca has received research support (to Tulane University) with grants from GlaxoSmithKline, Novartis, Novo Nordisk, Takeda, Astra-Zeneca, Pfizer, sanofi-aventis, Eli Lilly, Daiichi-Sankyo, Novartis, the National Institutes of Health (NIH) and the American Diabetes Association (ADA), and honoraria for consulting and lectures from GlaxoSmithKline, Novartis, Takeda, Pfizer, sanofi-aventis and Eli Lilly. J. McGill has received grant support (to Washington University) from sanofi-aventis, Pfizer, Eli Lilly, Novo Nordisk, Novartis, GlaxoSmithKline, Elixir, Tolerx, Biodel, MannKind, Takeda; served on advisory boards and speakers' bureaus for sanofi-aventis and Novo Nordisk, and on speakers' bureaus for Eli Lilly, Merck, Novartis, Daiichi-Sankyo, Forest and GlaxoSmithKline; and has been a consultant/advisor for Merck, Novo Nordisk, Elixir, MannKind and Amgen. I. Hramiak has received research grant support from Pfizer, sanofi-aventis, Novo Nordisk and Eli Lilly, and has served on advisory boards for GlaxoSmithKline, Novo Nordisk, sanofi-aventis and Merck. J.-P. Hallé has received grants for research from and/or has been a consultant and/or on the speaker bureau of Bristol-Myers Squibb, ConjuChem, Bellus Health, Eli Lilly, GlaxoSmithKline, Merck Frosst, Novartis, Novo Nordisk, Pfizer, Roche, sanofi-aventis and Takeda. M. Riddle has received grants for research and/or honoraria for consulting or lectures from Amylin, Lilly, the Amylin-Lilly Alliance, Novo Nordisk, Pfizer, sanofi-aventis and Valeritas. P. Johnston is an employee of, and holds stock options from sanofi-aventis. M. Davis has received research support from sanofi-aventis.
PY - 2009/9
Y1 - 2009/9
KW - Cancer
KW - Insulin analogues
KW - Insulin glargine
KW - Insulin therapy
KW - Malignancy
KW - NPH insulin
KW - Type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=68449088653&partnerID=8YFLogxK
U2 - 10.1007/s00125-009-1452-2
DO - 10.1007/s00125-009-1452-2
M3 - Letter
C2 - 19609501
AN - SCOPUS:68449088653
VL - 52
SP - 1971
EP - 1973
JO - Diabetologia
JF - Diabetologia
SN - 0012-186X
IS - 9
ER -